A Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989; IND-75,093) and Everolimus (RAD001; NSC-733504; IND-75,093) in Patients with Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2015
At a glance
- Drugs Everolimus (Primary) ; Lapatinib (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 23 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 04 Oct 2012 Planned end date changed from 1 Aug 2007 to 1 Oct 2013 as reported by ClinicalTrials.gov.